title: [Clinical-immunological aspects of multiple sclerosis treatment with ethylmethylhydroxypyridine succinate].
authors.forename: N F
authors.initials: NF
authors.lastname: Popova
authors.forename: E V
authors.initials: EV
authors.lastname: Orlova
authors.forename: M A
authors.initials: MA
authors.lastname: Pashchenkov
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko
mesh_terms: D000328:Adult; D018122:B7-1 Antigen / Q000032:analysis; D051940:B7-2 Antigen / Q000032:analysis; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology* / Q000523:psychology; D009483:Neuropsychological Tests; D011725:Pyridines / Q000627:therapeutic use*; D051195:Toll-Like Receptor 2 / Q000032:analysis; D051197:Toll-Like Receptor 4 / Q000032:analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018122:B7-1 Antigen; D051940:B7-2 Antigen; D011725:Pyridines; C495342:TLR2 protein, human; C495345:TLR4 protein, human; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; C517040:ethylmethylhydroxypyridine succinate